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Summary 
A number of previous studies have suggested a key role for intedeukin 7 (Ib7) in the maturation 
of T lymphocytes. To better assess the function of I1-7 in lymphopoiesis, we have deprived mice 
of IL-7 in vivo by long-term administration  of a neutralizing anti-IL-7 antibody.  In a previous 
report (Grabstein, K. H., T. J. Waldschmidt, F. D. Finkelman, B. W. Hess, A. R. Alpert, N. E. 
Boiani, A. E. Namen, and P. J. Morrissey. 1993..]. Exp. Med. 178:257-264), we used this system 
to demonstrate the critical role of I1-7 in B cell maturation. After a brief period of anti-It-7 
treatment, most of the pro-B cells and an of the pre-B and immature B cells were depleted 
from the bone marrow.  In the present report, we have injected anti-IL-7 antibody for periods 
of up to 12 wk to determine the effect of in vivo IL-7 deprivation  on the thymus.  The results 
demonstrate a >99% reduction in thymic cdlularity after extended periods of antibody adminis- 
tration. Examination of thymic CD4- and CD8- defined subsets revealed that, on a proportional 
basis, the CD4+, CD8+  subset was most depleted, the CD4 and CD8 single positive cells re- 
mained essentially unchanged, and the CD4-, CD8- compartment actually increased to "v50% 
of the thymus. Further examination of the double negative thymocytes demonstrated that I1-7 
deprivation  did, indeed, deplete the CD3-, CD4-, CD8-  precursors, with expansion of this 
subset being interupted at the CD44 +, CD25 +  stage. The proportional increase in the CD4-, 
CD8-  compartment was found to be due to an accumulation of CD3 +, T cell receptor ol,~ + 
double negative T cells. Additional analysis revealed that anti-Ib7 treatment suppressed the audi- 
tionAdection process of T cells, as shown by a significant reduction of single positive cells ex- 
pressing CD69 and heat stable antigen. Finally, the effects of I1-7 deprivation  on the thymus 
were found to be reversible, with a normal pattern of thymic subsets returning 4 wk after cessa- 
tion of treatment. The present results thus indicate a central  role for I1-7 in the maturation 
of thymic-derived T  cells. 
I 
1-7  has  been  demonstrated to  play  a  key role  in  the 
maturation of B lymphocytes (for review see reference 1). 
In addition to directly inducing growth of early B cells (2, 
3), studies have shown that the absence of Ib7 severely  com- 
promises B cell maturation (4-6). Consistent with these results, 
we recently demonstrated that short-term in vivo adminis- 
tration of an anti-It-7 antibody profoundly  blocks B cell de- 
velopment,  with  cells failing  to  progress  beyond the  $7 
(CD43)+, heat stable antigen (HSA)  tl~ pro-B cell stage (7). 
IL-7 has also been proposed  to promote the maturation 
of T cells, although its mode of action is less clear. Experi- 
ments have documented the presence of both I1-7 messenger 
RNA and protein in the thymus (2, 8, 9). In addition,  in 
1  Abbreviations used in this paper: BSS, balanced salt solution; DN, double 
negative; DE double positive; HSA, heat stable antigen; SP, single posi- 
tive; TN, triple negative; TSLP, thymic stromal-derived lymphopoietin. 
vitro studies have demonstrated the capacity of IL-7 to pro- 
mote the viability or growth of early T cells obtained from 
adult and fetal thymus (10-17), as well as costimulate thymo- 
cytes when cultured with Ib2 or mitogens (11, 13-15). Subset 
analysis of thymic T cells has indicated that IL-7 preferen- 
tially stimulates CD4 -, CD8- double negative (DN) T cells, 
especially those expressing I1-2 receptor (12, 16, 17). Addi- 
tional studies have suggested an effect of IL-7 on TCR rear- 
rangement. When cultured with I1-7, T cell precursors from 
thymus or fetal liver were found to express rearranged beta 
or gamma chain transcripts  (18-20). 
In vivo studies have further indicated a role for I1-7 in T 
cell development. Infusion of recombinant I1-7 into normal 
adult mice results in an increase of peripheral T cells and ac- 
celerates recovery of T cells in mice treated with irradiation 
or chemotherapy (21-24). Similar increases in T cell numbers 
are observed in 11-7 transgenic mice (25). When injecting 
an anti-IL-7 receptor antibody for 14 d, Nishikawa and co- 
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as well as a partial loss of peripheral  T cells (26).  Anti-Ib7 
antibody was also found to suppress  the capacity of thymic 
implants to reconstitute conventional T cells in athymic mice 
(27). In our previous study examining the effects of injected 
anti-IL-7 antibody on normal mice, a loss of thymic content 
was likewise observed after short-term treatment (7). Taken 
together, the various studies suggest an important function 
for IL-7 in T  cell maturation. 
In the present report, we have further assessed the require- 
ment for II.-7 in T cell maturation by injecting normal adult 
mice with high dose anti-IL-7 antibody for up to 12 wk. 
By neutralizing the cytokine in this manner, we were able 
to document the dependence of thymocyte maturation on 
IL-7 and characterize the effect of IL-7 deprivation on the var- 
ious thymic subsets. The results demonstrate a profound loss 
of thymic cellularity upon anti-IL-7 antibody injection, with 
a >99%  depletion of thymocytes at  12 wk of treatment. 
When examining the CD4- and CD8- defined subsets, it was 
found that on a proportional basis, the double positive (DP) 
population exhibited a substantial loss, the CD4 and CD8 
single positive (SP) subsets were unchanged, and the DN subset 
actually increased. The increase of  DN ceils was due to a greater 
proportion ofTCR ot,~ +  CD4-, CD8- T cells, and a reduc- 
tion  of the  CD3-,  CD4-,  CD8-  triple  negative  (TN) 
precursor population. Thus, in addition to playing a central 
role in B cell maturation, the present results strongly imply 
a similar role for IL-7 in T  cell development. 
Materials  and Methods 
Mice.  6-8-wk  old female BALB/c mice were obtained from 
Harlan Sprague Dawley, Inc. (Indianapolis, IN) and housed in 
specific pathogen-free investigator access rooms throughout the 
study. 
Antibodies for In  Vivo Treatment.  M25  (7), a  mouse IgG2b 
anti-human Ib7 monoclonal  antibody and Flag-M1 (7), an isotype- 
matched control, were purified from culture supernatants on pro- 
tein A affinity columns. The purified preparations contained <10 
pg of endotoxin/mg of antibody. 
Antibodies for Flow Cytoraetry.  For flow cytometric analysis,  the 
following antibodies were used: GK1.5, rat anti-mouse CD4 (28); 
53.6.72, rat anti-mouse CD8 (29); 145-2Cll, hamster anti-mouse 
CD3 (:30); H57-597, hamster anti-mouse TCR or,3 (31); 7D4, 
rat  anti-mouse  IL-2Rcr (32); 9F3, rat  anti-mouse  CD44  (33); 
M1/69, rat anti-mouse HSA (34); F23.1, rat anti-mouse V38 (35), 
and 6B2, a rat anti-mouse B220 (36). Antibodies were semipurified 
by 50% saturated ammonium sulfate  precipitation from serum-free 
supernatants (HB101) and were conjugated with FITC, biotin, and 
Cyanine 5.18, using standard  procedures. PE-conjugated  anti-CD3, 
anti-CD4, and anti-CD8 were purchased from PharMingen (San 
Diego, CA), as were biotin-labeled anti-murine CD69, antibodies 
to the VB3, V/~ll, and VB12 forms of the TCR. FITC-avidin and 
Texas Red-avidin were purchased from Vector Laboratories, Inc., 
Burlingame, CA. 
Treatment Protocol.  Mice  were injected intraperitoneally with 
1 nag of either M25 or Flag-M1 control antibody in a 100/~1 vol, 
three times per wk. Thymic cells were analyzed at 2, 4, 8, and 
12 wk of treatment. 
Cell Preparation. Thymic cells were dissociated  from the thymus 
by gently pressing the thymus glands between the frosted ends of 
two glass slides. The cells were suspended  in balanced salt solution 
(BSS) and washed by centrifugation  at  1,500 rpm  for 7 min. 
Mononuclear cells were isolated  by density gradient centrifugation 
(Lympholyte M; Cedarlane Laboratories, Ltd., Hornby, Canada). 
Cells were washed again in BSS and suspended  in staining solution 
(5% fetal  bovine  serum  in BSS + 0.1% sodium azide). Bone marrow 
ceUs were obtained by flushing out cells from the dissected femur 
and tibia with BSS, using a 30-gauge needle. Mononuclear cells 
were prepared as described above. 
Flow Cytometric Analysis.  Staining  was performed as a two-step 
procedure. 1  x  106 cells were suspended in staining buffer con- 
sisting of 5% serum and 0.1% NaN3 in BSS. The cells were, first, 
incubated with biotin, FITC, PE, or Cyanine 5.18-conjugated an- 
tibodies for 20 min at 4~  25 #g 2.4G2 antibody and 10 #1 normal 
rat serum were added to eliminate background staining due to Fc 
receptors. After washing, cells were further incubated with the ap- 
propriate avidin conjugate for 20 win at 4~  foUowed by addi- 
tional washings and subsequent FACS  |  analysis. Cells were run 
on a flow cytometer (FACS  |  440; Becton Dickinson & Co., Moun- 
tain View, CA) equipped with a primary argon ion hser and a rhoda- 
mine 6G CR599 dye head laser (Coherent, Inc., Palo Alto, CA), 
pumped by a second argon ion laser. 20 thousand cells were col- 
lected per sample. The FACS  |  440 data were collected and ana- 
lyzed using a VAX station 3200 computer (Digital Equipment 
Corp., Maynard, MA) equipped with DESK software (kindly sup- 
plied by Wayne Moore, Stanford University, Stanford, CA). Two- 
color contours are represented as 5% probability plots. 
Results 
M25  is a mouse anti-human IL-7 monoclonal antibody 
which cross-reacts with and neutralizes murine Ib7 (7). Since 
it is an autologous protein (BALB/c derived),  it can be given 
in high concentrations to mice for long periods of time without 
risk of an anti-IgG immune response.  The neutralizing ca- 
pacity of this antibody was demonstrated in a previous study, 
in which short-term administration of the M25 protein com- 
pletely blocked B cell maturation at an early stage  (7).  To 
similarly test the effect of IL-7 deprivation on T cell matura- 
tion, mice were treated from 2 to 12 wk with anti-Ib7 or 
control antibody, with each mouse receiving  1 mg of pro- 
tein three times a week. In data not shown, all mice treated 
with anti-IL-7 antibody lacked the prominent population of 
B221Y  ~  HSA  hi (early plus immature) B cells normally found 
in the bone marrow, indicating the effectiveness of the treat- 
ment over extended periods. 
When administrating the anti-Ib7 antibody to adult mice, 
the cell recovery from the thymus decreases dramatically, such 
that by 12 wk of treatment, a 99% reduction in thymic cel- 
lularity is observed (Fig. 1). This is in contrast to mice treated 
with control antibody, which maintained a normal level of 
thymocyte counts. Fig. 1 further demonstrates a biphasic loss 
of thymocytes, in that cellularity was rapidly lost during the 
first 2 wk of M25 administration, followed by a more gradual 
loss during the latter 10 wk. 
To assess the effect of IL-7 deprivation on the major thymic 
subsets, recovered calls were stained with antibodies to CD4 
and CD8, and the proportion of the four major populations 
was determined with flow cytometry. Although all popula- 
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tration of  anti-ID7 antibody.  Cell  counts  were  obtained  from  the suspended 
thymus glands of  adult BALB/c  mice  (three-five  per group)  intraperitoneally 
injected with 1 mg of monoclonal  anti-Ib7 antibody  three times a week 
for 2, 4, 8, or 12 wk. The control  group represents the mean of all mice 
similarly injected  with the isotype  matched mouse IgG. (12-wk control- 
treated thymus averaged  58  x  10~ recovered  cells). The data are shown 
as mean -+  SEM. 
tions experienced a loss in absolute numbers (Table  1), the 
CD4+, CD8+  (DP) subset was most affected on a percentage 
basis. Whereas the DP population normally composes ",'70% 
of the thymocyte  content, Fig. 2 demonstrates that this subset 
dropped to 25%  after 12 wk of anti-IL-7 treatment.  The 
proportion of CD4 and CD8 SP cells remained relatively un- 
changed, although there was a trend towards increased levels 
of CD4 SP cells in M25-treated mice. The percentage of CD4-, 
CDS- DN cells was also markedly affected, with an increase 
to almost 50% of the thymus upon long-term M25  treat- 
ment. Histologic examination of thymus tissue from treated 
mice was also  performed. In addition to a marked loss  of 
mass, fixed and stained (hematoxylin and eosin) tissue revealed 
a loss of structure and definition in the cortical zones, with 
retention of medullary morphology (data not shown). This 
is consistent with a loss of the immature stages. 
Table 1.  Total Cell Recovery per Thymic Subset 
Mean total cells  x  106 
Week  DN  DP  CD4 SP  CD8  SP 
Control  3.4  37.9  8.5  2.9 
2  1.6  5.8  3.2  1.5 
4  1.4  1.6  1.3  0.4 
8  0.9  0.9  1.0  0.3 
12  0.1  0.06  0.08  0.02 
Values were obtained  by multiplying  the total thymus cell recoveries  at 
2, 4, 8, and 12 wk of M25 treatment by the corresponding  percent for 
each population. Percentages  were obtained  flow cytometrically  using anti- 
CD4 and anti-CD8 staining. The control  group  values  represent  the mean 
of all mice injected with the isotype-matched  mouse IgG. 
Figure  2.  Anti-IL-7  treatment  alters the proportion  of  CD4- and CD8- 
defined  thymic  subsets. Thymic  cells  were  obtained  from mice  treated  for 
2-12 wk and processed  for flow cytometry  as described  in Materials and 
Methods. The cells  were  stained  with PE-conjugated  anti-CD4 and Cyanine- 
conjugated anti-CD8 before  flow cytometric  analysis. The percentage  of 
each  population  was calculated  by integration.  The control  group  represents 
the average  of  all mice  injected  with the isotype-matched  mouse  IgG. The 
values present the mean (three--five  mice per group) +_  SEM. 
Since the DN thymic subset is known to contain the least 
mature cells in the thymus, it was anticipated that this popu- 
lation would be most sensitive to the effects of II.-7 depriva- 
tion. It was curious, therefore, that the DN population was 
increased on a proportional basis with M25 administration. 
Three-color flow cytometry  was, therefore, used to assess the 
composition of the DN compartment, using antibodies to 
CD4 and CD8 in combination with a panel of other markers. 
Fig. 3 A  shows the CD4 vs. CD8 contour plots of animals 
treated with anti-IL-7 or control antibody for 8 wk. When 
analyzing the phenotype of the DN subset, as demonstrated 
in Fig.  3 B, it is clear that anti-IL-7 treatment (shaded histo- 
grams) markedly reduced the percentage of early thymocytes 
as compared to controls (open histograms). This is demonstrated 
by a marked drop in the CD25 +,  HSA+  subset.  Most of 
the DN cells at this time point are TCK c~,B +, CD5  hi, and 
CD44  hi. Consistent with previous reports, the level of TCR 
expression on these DN thymocytes is intermediate compared 
to mature SP cells (37, 38). The proportion of TCK 3',/i + 
thymic cells is not markedly different between anti-IL-7 and 
control-treated mice. It appears,  therefore, that the preferen- 
tial increase in the percentage of DN thymocytes results from 
the resistance ofDN TCR c~,/3 +  T cells to IL-7 deprivation. 
Fig. 4 illustrates the three-color flow cytometric analysis of 
DN thymocytes from mice treated for 2, 4, and 12 wk with 
anti-IL-7 (shaded histograms) or control (open histograms) anti- 
body. Together, these data clearly show a steady loss of the 
early thymic CD25 +, HSA+ compartment, such that by 12 
wk of anti-Ib7 treatment, virtually all of the DN  subset 
is composed of TCK o~,/3 +  T  cells.  Although the results 
indicate that long-term maintenance of the precursor popu- 
lation is  dependent upon IL-7,  the loss  of these cells  was 
progressive and not abrupt. This is in contrast to our previous 
studies on the B cell lineage, where IL-7 deprivation caused 
a rapid and complete loss of early B cells (7). Thus, whereas 
M25  treatment has  a pronounced effect on both B  and T 
cell precursors, the early B cell compartment appears much 
more sensitive to the deprivation of ILo7. 
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Figure 3.  Anti-IL-7 treatment depletes  a DN CD25+, CD44-, HSA+, 
CDS-, TCR oe,fl  + subset. Thymic cells from adult BALB/c  mice treated 
for 8 wk with anti-IL-7 or isotype-matched  control antibody were stained 
with conjugated antibodies and analyzed by three-color flow cytometry 
as described in  Materials and  Methods. Cells were stained with PE- 
conjugated  anti-CD4, Cyanine-conjugated  antiK2DS, and biotin-conjugated 
antibodies to CD25, CD44, HSA, CD5, TCR o~,fl, or TCR 'y,~ plus 
FITC-avidin. (A) Two-color  contours of CD4- and CDS-stained thymo- 
cytes. (B) Phenotype of CD4-, CDS-  gated thymocytes  from anti-IL-7 
(shaded histograms)- and control IgG (open histograms)-treated  mice. In A, 
the percentages  for the DN, DP, CD4 SP, and CD8 SP subsets are shown 
to the right of each contour plot. 
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Due to the predominance of TCR ot,B +  T  cells in the 
DN thymic subset of M25-treated mice, assessment of early 
precursors within the CD4-,  CD8-  compartment proved 
difficult. Further flow cytometric experiments, in which the 
CD3-,  CD4-,  CDS-  (TN) thymic population was exam- 
ined, were thus performed. As demonstrated by several in- 
vestigators, the precursor cells within the TN subset can be 
divided into progressive stages of maturation based upon CD44 
and CD25 expression (39-41). The earliest cells are reported 
to be CD44 +, CD25-, followed by the acquisition of CD25, 
the subsequent loss of CD44, and finally the loss of CD25. 
The CD44-, CD25-  cells then progress into the DP stage 
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Figure 4.  Early  thymocytes  are progressively  lost with anti-Ib7 treatment. Thymocytes from mice treated with M25 for 2, 4, and 12 wk (shaded 
histograms) or mice similarly treated with control antibody (open histograms) were stained with PE-conjugated anti-CD4, Cyanine-conjugated  anti-CD8, 
and biotin-conjugated antibodies to CD25, CD44, HSA, CD5, or CD3 plus FITC-avidin. The histograms are derived from the CD4-, CDS- gated 
populations. 
during which they complete TCR gene rearrangement,  ex- 
press the TCR, and undergo selection and final differentia- 
tion (for review see references 39 and 40). Thymocyte sus- 
pensions from mice treated for 4 wk with anti-IL-7 or control 
antibody were stained with antibodies to CD3, CD4, CDS, 
as well as CD25 and CD44.  Mice given antibody for only 
4 wk were used to ensure sufficient cell numbers for flow 
cytometric analysis. As shown in Fig. 5, the four CD25- and 
CD44- defined populations within the TN compartment of 
control  mice  are  easily  demonstrable,  with  the  CD25+, 
CD44 +  subset being the least numerous. When examining 
the thymus of M25-treated mice, three of the four popula- 
tions  are  greatly  reduced.  Whereas  the  earliest  CD44+, 
CD25-  subset is still easily seen, the remaining TN popula- 
tions  are diminished.  These data thus indicate that  IL-7 is 
used for thymocyte expansion,  beginning  at  the  CD44+, 
CD25+  stage. 
In addition to analyzing the DN and TN subsets of the 
thymus, the phenotype of the CD4+,CD8-,  CD4-,CD8 +, 
and the DP populations was assessed subsequent to anti-IL-7 
treatment.  Although the DP compartment  was greatly re- 
duced in M25-treated mice,  the overall  phenotype of these 
cells did not markedly differ when compared with  that  of 
control treated animals.  It was noted, however, that the DP 
cells of IL-7-deprived mice typically lacked the population 
of CD4 hi,  CD8 hi cells  seen in control  mice,  and consisted 
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primarily of CD41~  CD8  l~ cells (Fig.  3 A). This result be- 
came more pronounced  with  increasing  duration  of M25 
treatment. 
When examining  the CD4 and CD8 SP subsets, it was 
noted  that  anti-IL-7  treatment  reduced  or  eliminated  the 
HSA+  cells normally found within these populations. Since 
HSA+  cells within the SP populations are thought to repre- 
sent recently auditioned cells  (42),  we examined  the coor- 
dinate expression of HSA and CD69 on the CD4+, CD8- 
and CD4-, CD8+  subsets. Cells coexpressing HSA and CD69 
are those recently derived from the DP pool after having un- 
dergone TCR-mediated positive selection (43, 44). Thymo- 
cytes from mice treated for 4 wk with anti-IL-7 and control 
antibody were, therefore,  stained in a four-color protocol with 
antibodies to CD4, CD8, CD69, and HSA. The results shown 
in Fig. 6 demonstrate that IL-7 deprivation markedly reduced 
the HSA+,  CD69+  subset present  within each of the SP 
populations. This suggests that the lack of IL-7 either retards 
the rate at which cells progress through  the selection pro- 
cess, or, more likely, reduces the number of T cells available 
for selection events. Fig. 6 also shows the elimination of the 
HSA  hi, CD69-  cells within the CD8 SP population upon 
M25 treatment.  This subset is thought to represent cells in 
transit from the TN to the DP stage (45, 46), and thus ap- 
pears to be highly sensitive to II.,7 deprivation.  In data not 
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for the presence of V~3-, V~11-, and V~12-expressing cells 
after 4 wk of treatment. This was done to test whether anti- 
IL-7 administration  affected the deletion  of Mls  reactive T 
cells,  which normally occurs in I-E+ BALB/c mice. In both 
M25- and control-treated mice, V~3, VB11, and V/~12 posi- 
1600 
Figure  5.  TN thymoctyes  become  IL-7  responsive  at the CD44 +, 
CD25 + stage. Thymocytcs  from mice treated for 4 wk with anti-IL-7 
or control IgG were stained with PE-conjugated  antibodies to CD3, 
CD4, and CDS, Cyanine conjugated anti-CD25, and FITC-conju- 
gated anti-CD44. The TN population was gated as shown (top), to 
reveal the CD44- and CD25-defined subsets within this compart- 
ment. The CD3-, CD4-, CD8- gate in the anti-ID7-treated mouse 
was set lower to eliminate the large proportion of the CD31~ DN 
TCR c~,8 + calls. CD25 + cells were not eliminated due to the lower 
gating. The values refer to the percentage  of cells within each quad- 
rant of the TN compartment. 
tive T cells were absent in the SP populations, with a normal 
representation  of VB8-expressing cells.  Under these condi- 
tions,  therefore,  it  appears that  neutralization  of IL-7 does 
not  affect thymic negative  selection. 
Given the striking reduction of thymic cellularity upon 
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Figure 6.  Anti-ID7 treatment markedly reduces thymocytes  un- 
dergoing sdection events. Thymoctyes from mice treated for 4 wk 
with M25 or control IgG were stained with PE-conjugated  anti-CD4, 
Cyanine-conjugated anti-CDS, FITC-conjugated anti-HSA, and 
biotin-conjugated anti-CD69 plus Texas Ked-avidin. The CD69 vs. 
HSA contours  are derived  from the CD4+, CDS- and CD4--, CD8+ 
gated populations. 
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Figure  7.  The effects oflL-7 deprivation on thymic maturation are reversible. Mice injected with M25 for 8 wk, followed by withdrawal of treatment 
for 2 wk (.4) or 4 wk (B). Thymocytes were stained with PE-conjugated anti-CD4, Cyanine-conjugated anti-CDS, and biotin-conjugated antibodies 
to CD25, CD44, HSA, or TCK oz,B, plus FITC-avidin. The histograms are derived from the CD4-,  CDS-  gated populations, as shown (top).  The 
percentages for each of the populations are as follows: 2-wk thymus; DN  =  32.2%, DP  =  39.1%, CD4 SP  =  24.1%, CD8 SP =  4.5%. 4-wk thymus; 
DN  =  7.4%,  DP  =  72.6%,  CD4  SP  =  17.6%,  CD8  SP  =  2.2%. 
anti-IL-7  injection,  we next sought to examine the reversi- 
bility of IL-7 deprivation.  After 8 wk of M25 treatment, mice 
were allowed to rest for either 2 or 4 wk, with subsequent 
flow cytometric analysis of the thymus. Fig. 7 A demonstrates 
that after 2 wk of release, the thymus is still abnormal with 
a skewed proportion of the CD4- and CD8-defined subsets 
and a reduced level of precursors. Also noteworthy is the con- 
tinued  reduction  of the  CD4  hi,  CD8  hi  subset  in  the DP 
population. By 4 wk after the last M25 injection,  however, 
the thymus has returned to a normal phenotype (Fig. 7 B). 
In  addition  to  a greater  number  of CD25+,  HSA+  DN 
precursors, the CD4- and CDS-defmed subsets appear normal, 
and the range of CD4 and CD8 expression levels in the DP 
population is now similar to that of control mice. Interest- 
ingly,  thymic recovery averaged only 2.5  x  106 total cells 
after 4 wk of release. These findings indicate that, although 
normal patterns of thymic maturation reappear in a matter 
of weeks, greater periods of time may be required for reestab- 
lishing  normal cell numbers upon withdrawal of the neu- 
tralizing  antibody. 
Discussion 
A number of previous studies have demonstrated the ca- 
pacity of IL-7 to support the viability or growth of thymo- 
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a role for Ib7 in the maturation  of T  cells,  it was unclear 
as to whether this cytokine is central to the process of early 
T  cell expansion.  The present report directly examines the 
issue by depriving IL-7 in vivo and following the fate of the 
thymic compartment.  After extended administration  of an 
anti-Ib7 antibody, >99% of the thymic cellularity was lost, 
compared to control treated mice. The drop in thymic cell 
counts was accompanied by a preferential  loss of the TN 
precursor and DP populations, and retention of mature TCR 
c~,~ +  subsets. Together with previous results showing a crit- 
ical need for IL-7 in B cell maturation (7), these data demon- 
strate  IL-7 to be a key cytokine in  the  establishment  and 
replenishment  of the lymphoid system. 
The present results clearly agree with earlier in vitro studies 
showing the capacity of Ib7 to support early T cell growth 
(10-17). The finding that in vivo anti-Ib7 treatment depletes 
the  TN  thymic  compartment,  beginning  at  the  CD44+, 
CD25+  stage  (Fig.  5),  confirms  the  previous  reports  of 
Watson et al.  (12) and Plum et al.  (17) demonstrating  the 
preferential  growth  of TN  cells  of this  phenotype  in  IL- 
7-driven  fetal  thymic cultures.  Since the earliest  CD44+, 
CD25-  TN subset was retained in mice given M25, it would 
appear that  early T  cells  become responsive to  Ib7 at  the 
CD44+,  CD25+  TN stage.  This responsiveness could be 
due to the surface expression of the II.-7 receptor, or to the 
acquisition of the IL-2 receptor "y-chain, a component neces- 
sary for IL-7 receptor-mediated signal transduction (47, 48). 
The latter possibility is consistent with cells of this stage ex- 
pressing CD25,  the or-chain  of the IL-2 receptor complex. 
Several reports describing in vivo experiments are, likewise, 
consistent with our data. Kenai et al. demonstrated that ad- 
ministration  of an anti-IL-7  antibody reduces the capacity 
of fetal  thymic tissue, implanted  in diffusion chambers,  to 
promote T cell maturation in athymic mice (27).  Nishikawa 
and co-workers further showed that injection of a rat anti- 
mouse IL-7 receptor antibody results in a marked reduction 
of thymic cellularity after 2 wk of administration  (26).  As 
in  the present  study,  these investigators  found the thymic 
DP population to be most affected upon disruption of IL-7 
use. Our findings,  thus, confirm and extend these previous 
studies. 
Although all thymic subsets were reduced in number upon 
M25 administration,  the CD4 SP, CD8 SP and DN TCR 
ot,/~ +  T cells were least affected on a proportional basis. Four- 
color flow cytometric analysis  showed most of the SP cells 
in anti-Ib7-treated mice to be HSA and CD69 negative.  This 
indicates that the majority of the SP thymocytes in treated 
animals are either postselected cells ready for export (42-44), 
or mature calls returned from the periphery. The persistence 
of the DN TCR oe,/~ +  thymocytes is also of interest.  Previous 
investigators  have shown these cells to appear late in ontogeny 
(38, 49), express  a skewed VB repertoire (38, 49),  and ex- 
hibit cytolitic activity (50, 51). Additional studies have sug- 
gested a portion of these cells to be extrathymically derived, 
perhaps arising in the liver or gut (for review see reference 
52). The observation that DN TCR c~,3 +  T cells compose 
most of the DN compartment in anti-Ib7-treated mice sug- 
gests either  that  maturation  of these cells  is insensitive to 
the effects  of M25,  or that  these may also be mature cells 
derived from the periphery. On a proportional basis, the con- 
tent  of DN  TCR  y,t3 +  thymic  T  cells  did  not  change. 
Whether this indicates a minimal role for Ib7 in y,/~ T cell 
growth is presently unclear. A careful examination  of peripheral 
T  cell sites in M25-treated  mice will be necessary to fully 
assess the importance of IL-7 on the persistence of the y,~5 
T  cell population. 
Whereas a brief treatment  with M25 resulted in a com- 
plete block of B cell maturation  (7),  significant  depletion 
(>90%) of early T cells required extended periods of anti-IL-7 
administration.  The reason for this difference is presently un- 
known, but several possibilities exist. It could be argued that 
the murine IgG2b antibody has greater accessibility to crit- 
ical sites in the bone marrow than in the thymus and, hence, 
requires an extended injection schedule for thymic depletion. 
Earlier studies have shown, however, that injection of mouse 
IgG2b antibodies against MHC class I (53) or class II (54) 
molecules is very effective in interfering  with  CD4+  and 
CDS+  T  cell development,  indicating  full access of these 
antibodies to thymic tissue.  A second possibility is that IL-7 
is simply an expansion  factor for early T  cells,  and,  in its 
absence,  T cells rapidly proceed through their maturational 
program. Should this be the case, the progressive loss of early 
and intermediate T cell blasts, but not a complete shutdown 
of development would be observed. Finally,  the possibility 
arises  that,  in the absence of Ib7,  thymocytes may be able 
to use another cytokine during the critical TN stage, albeit 
to a lesser extent. Recent investigation has shown significant 
overlap of the biologic activities of certain cytokine pairs. Ex- 
amples of this include the redundant  activities of IL-4 and 
IL-13 (for review see reference 55),  as well as the activities 
of IL-2 and IL-15 (56, 57). It is interesting to note that a new 
factor, termed thymic stromal-derived lymphopoietin (TSLP), 
has been cloned and does, indeed, exhibit some of the same 
activities as IL-7 (58). The role of TSLP in lymphocyte matu- 
ration  awaits further  testing. 
Together with studies on human SCID and experiments 
with cytokine-deficient mice, the data in this report clearly 
demonstrate a central role for IL-7 in T  cell maturation.  It 
is now understood that  manifestations  of human  X-linked 
SCID are due to mutations in the y-chain of the Ib2 receptor 
(for review see reference 59).  To date,  IL-2, IL-4,  II.-7, and 
IL-15 are known to require the y-chain for signal transduc- 
tion. The inability of SCID patients to use these cytokines 
thus contributes  to  their lack of T  cell development.  The 
question arises as to which of the lost activities is primarily 
responsible for the defect in maturation.  In mice made ge- 
netically deficient for IL-2 (60) or II.-4 (61), development of 
the T cell compartment proceeds normally. This even holds 
true in offspring of IL-2-deficient  x  IL-4-deficient parents 
(62).  Thus, while II.,2 and IL-4 are not crucial for lympho- 
cyte development, the profound effects of in vivo M25 treat- 
ment suggest II.,7 to be a key signal  in early T cell matura- 
tion. The effects of II_,15 on early lymphocytes remain to be 
determined.  The present results are also in good agreement 
with studies on mice genetically deficient for the IL-7 receptor 
1406  The Effect of In Vivo Anti-lL-7 on T Cell Maturation (63). These mice exhibit thymic cellularity ranging from 0.01 
to 10% of normal thymus, and similarly display a deficit of 
early CD25 +  T cells. Finally, it is well established that the 
thymus undergoes significant atrophy upon aging. Since ex- 
tended deprivation of IL-7 in young adult mice results in a 
similar phenomenon, it is possible that the natural process 
of thymic atrophy results  from a  local shutdown  of Ib7 
production. 
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